

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of
WILS, ET AL

Examiner: Ketter, J.

Serial No.: 09/153,838

Art Unit: 1636

Filed: September 15, 1998

Title: **PURIFICATION OF PLASMID DNA
OF PHARMACEUTICAL QUALITY**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile 703-305-7939
to the Commissioner for Patents, Washington, D.C.
20231, on

July 9, 2001

Date of Transmission

Signature

Doan Shin

RESPONSE TO FINAL ACTION UNDER 37 CFR 1.116

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Final Office Action dated April 18, 2001, please amend the above-identified application as follows.

IN THE CLAIMS

Please cancel claims 25 and 26 without prejudice.

REMARKS

The Examiner's indication that claims 1-22 are allowed is noted with appreciation.

In order to expedite the allowance of these claims, Applicants have cancelled claims 25 and 26, thereby obviating the only rejection set forth in the Office Action.

Accordingly, favorable reconsideration and prompt Notice of Allowance are earnestly solicited.

Respectfully submitted,

Irving Newman
Irving Newman, Reg. No. 22,638
Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2785
Telefax (908) 231-2626
File: ST96016-US

RECEIVED AS
OFFICIAL
TC 1600 FAX CENTER
7/9/01

PLEASE
ENTER
PH
7/10/01

#17/D
MK
7/10/01

**FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE****Applicants Docket Number:**
ST96016-US**Applicants:**
Wills, et al**Serial No.**
09/153,838**Filing Date:**
September 15, 1998**Title of Invention:**
PURIFICATION OF PLASMID DNA OF PHARMACEUTICAL QUALITY**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, Washington, D.C. 20231,
at 703-305-7939, on
Date of Deposit July 9, 2001
Printed Name of Person Signing Certificate Bonnie Stein
Signature *Bonnie Stein*

Total Number of Pages Sent: 2**Attorney:** Irving Newman**Group Art Unit:** 1636**Examiner:** J. Ketter**TO:** Commissioner for Patents
Box
Washington, D.C. 20231

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit
account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- | | |
|--|--|
| <input checked="" type="checkbox"/> Amendment, 37 CFR 1.116 | <input type="checkbox"/> Maintenance Fee Transmittal |
| <input type="checkbox"/> Assignment & Cover Sheet | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR |
| <input type="checkbox"/> Extension of Time Petition | <input type="checkbox"/> Other |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other |

Receipt Confirmed:_____
Signed_____
Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)